Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial

Karan Bami; Sumeet Gandhi; Howard Leong-Poi; Andrew T. Yan; Edwin Ho; Mohammed Zahrani; Vinay Garg; Fei Zuo; Hwee Teoh; Adrian Quan; Lawrence A. Leiter; Richard E. Gilbert; Bernard Zinman; Kevin E. Thorpe; Peter Jüni; C. David Mazer; Subodh Verma; Geraldine Ong; Kim A. Connelly

doi:10.1016/j.echo.2020.02.005

Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial

Karan Bami, Sumeet Gandhi, Howard Leong-Poi, Andrew T. Yan, Edwin Ho, Mohammed Zahrani, Vinay Garg, Fei Zuo, Hwee Teoh, Adrian Quan, Lawrence A. Leiter, Richard E. Gilbert, Bernard Zinman, Kevin E. Thorpe, Peter Jüni, C. David Mazer, Subodh Verma, Geraldine Ong, Kim A. Connelly

Medicine

Research output: Contribution to journal › Letter › peer-review

17 Scopus citations

Original language	English (US)
Pages (from-to)	644-646
Number of pages	3
Journal	Journal of the American Society of Echocardiography
Volume	33
Issue number	5
DOIs	https://doi.org/10.1016/j.echo.2020.02.005
State	Published - May 2020

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging
Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.echo.2020.02.005

Cite this

Bami, K., Gandhi, S., Leong-Poi, H., Yan, A. T., Ho, E., Zahrani, M., Garg, V., Zuo, F., Teoh, H., Quan, A., Leiter, L. A., Gilbert, R. E., Zinman, B., Thorpe, K. E., Jüni, P., Mazer, C. D., Verma, S., Ong, G., & Connelly, K. A. (2020). Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial. Journal of the American Society of Echocardiography, 33(5), 644-646. https://doi.org/10.1016/j.echo.2020.02.005

Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial. / Bami, Karan; Gandhi, Sumeet; Leong-Poi, Howard et al.
In: Journal of the American Society of Echocardiography, Vol. 33, No. 5, 05.2020, p. 644-646.

Research output: Contribution to journal › Letter › peer-review

Bami, K, Gandhi, S, Leong-Poi, H, Yan, AT, Ho, E, Zahrani, M, Garg, V, Zuo, F, Teoh, H, Quan, A, Leiter, LA, Gilbert, RE, Zinman, B, Thorpe, KE, Jüni, P, Mazer, CD, Verma, S, Ong, G & Connelly, KA 2020, 'Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial', Journal of the American Society of Echocardiography, vol. 33, no. 5, pp. 644-646. https://doi.org/10.1016/j.echo.2020.02.005

Bami K, Gandhi S, Leong-Poi H, Yan AT, Ho E, Zahrani M et al. Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial. Journal of the American Society of Echocardiography. 2020 May;33(5):644-646. doi: 10.1016/j.echo.2020.02.005

@article{be113225678d44008febe3f85d290742,

title = "Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial",

author = "Karan Bami and Sumeet Gandhi and Howard Leong-Poi and Yan, {Andrew T.} and Edwin Ho and Mohammed Zahrani and Vinay Garg and Fei Zuo and Hwee Teoh and Adrian Quan and Leiter, {Lawrence A.} and Gilbert, {Richard E.} and Bernard Zinman and Thorpe, {Kevin E.} and Peter J{\"u}ni and Mazer, {C. David} and Subodh Verma and Geraldine Ong and Connelly, {Kim A.}",

note = "Funding Information: This trial was supported by an unrestricted investigator-initiated study grant from Boehringer Ingelheim to Drs. Verma and Zinman. The study sponsor was not involved in the study design; data collection, analysis, and interpretation; the writing of this report; or the decision to submit for publication. Funding Information: This trial was supported by an unrestricted investigator-initiated study grant from Boehringer Ingelheim to Drs. Verma and Zinman. The study sponsor was not involved in the study design; data collection, analysis, and interpretation; the writing of this report; or the decision to submit for publication.Dr. Bami has received support for travel to scientific meetings from Boehringer Ingelheim. Dr. Yan has received research support from AstraZeneca. Dr. Teoh has received an honorarium from Boehringer Ingelheim and writing fees for unrelated diabetes-focused reports from Merck and Servier. Dr. Leiter has received grants and/or honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novo Nordisk, Sanofi, and Servier outside the submitted work. Dr. Gilbert holds a Canada Research Chair in Diabetes Complications; has received research grants to the institution from AstraZeneca and Boehringer Ingelheim; serves on advisory panels for AstraZeneca, Boehringer Ingelheim, and Janssen; and has received continuing medical education speaking honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Janssen. Dr. Zinman has received research support from Boehringer Ingelheim and serves as a consultant for AstraZeneca, Eli Lilly, Janssen, Merck, Novo Nordisk, and Sanofi. Dr. J{\"u}ni holds a Canada Research Chair in Clinical Epidemiology of Chronic Diseases; has received research grants to the institution from AstraZeneca, Biosensors International, Biotronik, Eli Lilly, and The Medicines Company; and serves as an unpaid member of the steering groups for trials funded by AstraZeneca, Biosensors International, Biotronik, St. Jude Medical, and The Medicines Company. Dr. Mazer has received honoraria from Amgen, Boehringer Ingelheim, and OctaPharma. Dr. Verma holds a Canada Research Chair in Cardiovascular Surgery and has received research grants and/or speaking honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, EOCI Pharmacomm, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, Sun Pharmaceuticals, and the Toronto Knowledge Translation Working Group. Dr. Verma is also president of the Canadian Medical and Surgical Knowledge Translation Research Group, a federally incorporated not-for-profit physician organization. Dr. Connelly is listed as an inventor on a patent application by Boehringer Ingelheim on the use of dipeptidyl peptidase-4 inhibitors in heart failure; has received research grants to the institution from AstraZeneca and Boehringer Ingelheim; has received support for travel to scientific meetings from Boehringer Ingelheim; and has received honoraria for speaking engagements and ad hoc participation in advisory boards from AstraZeneca, Boehringer Ingelheim, and Janssen.",

year = "2020",

month = may,

doi = "10.1016/j.echo.2020.02.005",

language = "English (US)",

volume = "33",

pages = "644--646",

journal = "Journal of the American Society of Echocardiography",

issn = "0894-7317",

publisher = "Mosby Inc.",

number = "5",

}

TY - JOUR

T1 - Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease

T2 - Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial

AU - Bami, Karan

AU - Gandhi, Sumeet

AU - Leong-Poi, Howard

AU - Yan, Andrew T.

AU - Ho, Edwin

AU - Zahrani, Mohammed

AU - Garg, Vinay

AU - Zuo, Fei

AU - Teoh, Hwee

AU - Quan, Adrian

AU - Leiter, Lawrence A.

AU - Gilbert, Richard E.

AU - Zinman, Bernard

AU - Thorpe, Kevin E.

AU - Jüni, Peter

AU - Mazer, C. David

AU - Verma, Subodh

AU - Ong, Geraldine

AU - Connelly, Kim A.

N1 - Funding Information: This trial was supported by an unrestricted investigator-initiated study grant from Boehringer Ingelheim to Drs. Verma and Zinman. The study sponsor was not involved in the study design; data collection, analysis, and interpretation; the writing of this report; or the decision to submit for publication. Funding Information: This trial was supported by an unrestricted investigator-initiated study grant from Boehringer Ingelheim to Drs. Verma and Zinman. The study sponsor was not involved in the study design; data collection, analysis, and interpretation; the writing of this report; or the decision to submit for publication.Dr. Bami has received support for travel to scientific meetings from Boehringer Ingelheim. Dr. Yan has received research support from AstraZeneca. Dr. Teoh has received an honorarium from Boehringer Ingelheim and writing fees for unrelated diabetes-focused reports from Merck and Servier. Dr. Leiter has received grants and/or honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novo Nordisk, Sanofi, and Servier outside the submitted work. Dr. Gilbert holds a Canada Research Chair in Diabetes Complications; has received research grants to the institution from AstraZeneca and Boehringer Ingelheim; serves on advisory panels for AstraZeneca, Boehringer Ingelheim, and Janssen; and has received continuing medical education speaking honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Janssen. Dr. Zinman has received research support from Boehringer Ingelheim and serves as a consultant for AstraZeneca, Eli Lilly, Janssen, Merck, Novo Nordisk, and Sanofi. Dr. Jüni holds a Canada Research Chair in Clinical Epidemiology of Chronic Diseases; has received research grants to the institution from AstraZeneca, Biosensors International, Biotronik, Eli Lilly, and The Medicines Company; and serves as an unpaid member of the steering groups for trials funded by AstraZeneca, Biosensors International, Biotronik, St. Jude Medical, and The Medicines Company. Dr. Mazer has received honoraria from Amgen, Boehringer Ingelheim, and OctaPharma. Dr. Verma holds a Canada Research Chair in Cardiovascular Surgery and has received research grants and/or speaking honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, EOCI Pharmacomm, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, Sun Pharmaceuticals, and the Toronto Knowledge Translation Working Group. Dr. Verma is also president of the Canadian Medical and Surgical Knowledge Translation Research Group, a federally incorporated not-for-profit physician organization. Dr. Connelly is listed as an inventor on a patent application by Boehringer Ingelheim on the use of dipeptidyl peptidase-4 inhibitors in heart failure; has received research grants to the institution from AstraZeneca and Boehringer Ingelheim; has received support for travel to scientific meetings from Boehringer Ingelheim; and has received honoraria for speaking engagements and ad hoc participation in advisory boards from AstraZeneca, Boehringer Ingelheim, and Janssen.

PY - 2020/5

Y1 - 2020/5

UR - http://www.scopus.com/inward/record.url?scp=85082751432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85082751432&partnerID=8YFLogxK

U2 - 10.1016/j.echo.2020.02.005

DO - 10.1016/j.echo.2020.02.005

M3 - Letter

C2 - 32199780

AN - SCOPUS:85082751432

SN - 0894-7317

VL - 33

SP - 644

EP - 646

JO - Journal of the American Society of Echocardiography

JF - Journal of the American Society of Echocardiography

IS - 5

ER -

Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this